Abstract
The mammalian target of rapamycin, mTOR, is a Ser/Thr kinase that promotes cell growth and proliferation by activating ribosomal protein S6 kinase 1 (S6K1). We previously identified a conserved TOR signaling (TOS) motif in the N terminus of S6K1 that is required for its mTOR-dependent activation. Furthermore, our data suggested that the TOS motif suppresses an inhibitory function associated with the C terminus of S6K1. Here, we have characterized the mTOR-regulated inhibitory region within the C terminus. We have identified a conserved C-terminal "RSPRR" sequence that is responsible for an mTOR-dependent suppression of S6K1 activation. Deletion or mutations within this RSPRR motif partially rescue the kinase activity of the S6K1 TOS motif mutant (S6K1-F5A), and this rescued activity is rapamycin resistant. Furthermore, we have shown that the RSPRR motif significantly suppresses S6K1 phosphorylation at two phosphorylation sites (Thr-389 and Thr-229) that are crucial for S6K1 activation. Importantly, introducing both the Thr-389 phosphomimetic and RSPRR motif mutations into the catalytically inactive S6K1 mutant S6K1-F5A completely rescues its activity and renders it fully rapamycin resistant. These data show that the N-terminal TOS motif suppresses an inhibitory function mediated by the C-terminal RSPRR motif. We propose that the RSPRR motif interacts with a negative regulator of S6K1 that is normally suppressed by mTOR.
Highlights
Summary—We have identified a highly conserved motif (RSPRR) within the C terminus of S6K1 that mediates an inhibitory effect on mTOR-dependent S6K1 activation
We anticipate that future work will reveal the identity of the RSPRR-associated negative regulator
The full-length rapamycin-resistant S6K1 mutant (S6K1-F5A-E389 –3A) described in this study will be a useful tool to study rapamycin-sensitive signaling through S6K1
Summary
Plasmids and Mutagenesis—The HA-S6K1 (wild-type, HA-S6K1⌬CT401, HA-S6K1-F5A, HA-S6K1-F5A-⌬CT401, and HA-S6K1-F5AE389⌬CT401) constructs were generated as previously described (9). Point mutations were introduced using the QuikChange PCR method (Stratagene). C-terminal truncation S6K1 mutants were generated by introducing a premature stop codon into the coding sequence of S6K1. Antibodies—Anti-HA antibodies were kindly provided by M. The anti-S6K1-phosphoThr-389 and -Thr-229 antibodies were obtained from Cell Signaling Inc. (Beverly, MA) and R&D Systems (Minneapolis, MN), respectively. The Ser-371 antibody was described previously (9)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.